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Facilitation of neuropathic pain by 
the NPY Y1 receptor-expressing 
subpopulation of excitatory 
interneurons in the dorsal horn
tyler s. Nelson1,2, Weisi Fu3, Renée R. Donahue3, Gregory F. Corder3,4, Tomas Hökfelt5, 
Ronald G. Wiley6 & Bradley K. taylor1,3
Endogenous neuropeptide Y (NPY) exerts long-lasting spinal inhibitory control of neuropathic pain, 
but its mechanism of action is complicated by the expression of its receptors at multiple sites in the 
dorsal horn: NPY Y1 receptors (Y1Rs) on post-synaptic neurons and both Y1Rs and Y2Rs at the central 
terminals of primary afferents. We found that Y1R-expressing spinal neurons contain multiple markers 
of excitatory but not inhibitory interneurons in the rat superficial dorsal horn. To test the relevance 
of this spinal population to the development and/or maintenance of acute and neuropathic pain, we 
selectively ablated Y1R-expressing interneurons with intrathecal administration of an NPY-conjugated 
saporin ribosomal neurotoxin that spares the central terminals of primary afferents. NPY-saporin 
decreased spinal Y1R immunoreactivity but did not change the primary afferent terminal markers 
isolectin B4 or calcitonin-gene-related peptide immunoreactivity. In the spared nerve injury (SNI) model 
of neuropathic pain, NPY-saporin decreased mechanical and cold hypersensitivity, but disrupted neither 
normal mechanical or thermal thresholds, motor coordination, nor locomotor activity. We conclude 
that Y1R-expressing excitatory dorsal horn interneurons facilitate neuropathic pain hypersensitivity. 
Furthermore, this neuronal population remains sensitive to intrathecal NPY after nerve injury. 
This neuroanatomical and behavioral characterization of Y1R-expressing excitatory interneurons 
provides compelling evidence for the development of spinally-directed Y1R agonists to reduce chronic 
neuropathic pain.
Peripheral nerve damage can lead to a debilitating neuropathic pain syndrome that persists for years1. Even the 
most powerful opioid analgesics lack reliable efficacy, and instead cause an unacceptable set of adverse effects 
that often includes addiction2. To address this problem, distinct populations of excitatory interneurons have been 
identified within the spinal dorsal horn microcircuitry that are required for the behavioral expression of neuro-
pathic pain3–8. These subpopulations can be defined by the expression of either a small molecule neurotransmitter 
(e.g. gamma-aminobutyric acid, GABA), a neuropeptide transmitter (e.g. somatostatin)5, transporter protein (e.g. 
vesicular glutamate transporter 3, VGlut3)7, or opioid receptor (e.g. DOR)8; however, none of these neural popu-
lation have been found to be readily druggable targets for the development of pharmacological agents directed at 
non-opioid neurotransmitter receptors.
Both exogenous and endogenous NPY acts at Y1Rs within the dorsal horn to inhibit neuropathic pain. 
Intrathecal administration of NPY or the Y1 receptor agonist Leu31 Pro34 NPY dose-dependently reduced 
mechanical and cold hypersensitivity after spared sural nerve injury9,10 or chronic constriction injury to the sciatic 
nerve11. Likewise, either conditional NPY knockdown in NPYtet-transgenic mice or intrathecal administration of 
the Y1R antagonist BIBO 3304 elicited a robust and reliable increase in cold and mechanical hyperersensitivity12, 
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indicating that neuropathic hyperalgesia is tonically inhibited by NPY that is endogenously released within the 
dorsal horn.
Y1Rs are highly expressed at the dorsal horn of the spinal cord, including several populations of small 
interneurons located throughout laminae I–III13–17. Immunohistochemical studies have localized Y1R to the den-
drites and somas of somatostatin-positive dorsal horn neurons18. Since this population expresses VGLUT1 and 
VGLUT219,20, Y1R-expressing cells have been presumed to be glutamatergic, and thus excitatory17,21. Indeed, we 
have postulated that Y1R-expressing cells are excitatory interneurons under an NPY-mediated inhibitory influ-
ence22; however, rigorous immunohistochemical co-labeling of Y1R cell bodies in wild-type (non-transgenic) 
spinal cord tissue with markers of excitatory neurons has been difficult to interpret due to the intense plexus of 
dendritic and terminal staining that surrounds Y1R-positive cells. To enhance Y1R resolution within dorsal horn 
neurons, we developed and evaluated a new intrathecal NPY injection strategy to promote receptor internaliza-
tion, thereby concentrating Y1R from more distal dendritic locations to within the cell soma; the enhanced signal 
allowed quantification of Y1R co-localization with multiple markers of excitatory and inhibitory interneurons.
Next, to address the functional significance of spinal Y1R-expressing neurons to the development of neu-
ropathic pain, we selectively lesioned Y1R-expressing dorsal horn interneurons using intrathecal admin-
istration of the NPY-conjugated ribosomal toxin, NPY-saporin21–24. NPY-saporin selectively, reliably, and 
dose-dependently delivers the cytotoxic ribosome inactivating protein, saporin, into Y1R neurons following 
NPY Y1 receptor-mediated endocytosis21,24. As with other peptide-saporin conjugates, NPY-saporin is selec-
tively internalized by somatodendritic Y1 receptors on dorsal horn interneurons, while sparing axon terminals 
including those of Y1R-expressing DRG neurons21. Our approach, which uses NPY-saporin, readily discriminates 
between targets on cell bodies and axon terminals21, and avoids pitfalls associated with the use of Y1R-Cre trans-
genic mice that include germline recombination, transient expression, and aberrant expression at non-targeted 
sites25.
Methods
Animals. Male Sprague-Dawley rats (Charles Rivers Laboratories), delivered at 165–205 g and weighing 235–
260 g at time of surgery were used throughout the study. Animals were housed in a temperature-controlled room 
on a 12-hr light/dark cycle and were given chow and water ad libitum. All animal use protocols were approved 
by the IACUC of the University of Kentucky. All experiments and methods were performed in accordance with 
institutional relevant guidelines and regulations and in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals.
Intrathecal delivery of NPY and NPY-saporin. NPY. Our initial attempts to visualize Y1R cell bod-
ies failed due to the high background staining from the dense plexus of central terminals of primary afferent 
neurons, as noted previously15. To overcome this problem, Brumovsky et al. used tyramide signal amplification 
(TSA) method combined with confocal imaging in thin optical sections to visualize Y1R-expressing cell bodies15. 
Here, we used an alternative approach to enhance visualization of Y1R interneurons: we delivered spinal NPY to 
promote receptor internalization, thereby concentrating Y1R from more distal dendritic locations to within the 
cell soma. This was achieved following two intrathecal injections of NPY (30 µg) separated by 1 hour. One hour 
after the second injection, rats were deeply anesthetized with isoflurane and perfused with 0.1 M PBS containing 
heparin (10,000 USP units/L) followed by 10% buffered formalin.
NPY-Saporin. To selectively ablate spinal Y1R-expressing interneurons, the saporin-conjugated peptide 
NPY-saporin, or a control blank-saporin (Advanced Targeting Systems, San Diego, CA) was intrathecally injected 
at the lumbar level in a volume of 10 μl using a 25 μl Hamilton microsyringe attached to a 27-gauge disposable 
sterile needle under isoflurane anesthesia (5% induction; 1.5–2% maintenance). Blank saporin is an 11-amino 
acid, randomly-mixed version of the sequence of melanocyte-stimulating hormone. Its amino acid residues are 
typical of peptides that bind to G-protein-coupled receptors although this random peptide has no homologous 
sequences that which it can bind to in vivo. Blank-saporin was delivered at a 1000 ng dilution. The needle was 
inserted into the subarachnoid space through the intervertebral foramen. A tail flick response was used as ver-
ification of correct placement of the needle and successful saporin delivery was verified via decreases in Y1R 
immunoreactivity.
Spared nerve injury (SNI) surgery. Fourteen days after intrathecal NPY-saporin or blank-saporin injec-
tion, animals underwent SNI surgery. SNI was performed as described previously9,26. Anesthesia was induced 
and maintained with 5% and 2–3% isoflurane, respectively. After shaving and Betadine wipe of the left hind 
limb, an incision was made in the skin at the level of the trifurcation of the left sciatic nerve. The overlying biceps 
femoris muscles were retracted, exposing the tibial, common peroneal, and sural nerve branches. The common 
peroneal and tibial nerves were ligated with 6-0 silk (Ethicon, Somerville, NJ), and then the knot and adjacent 
nerve (2 mm) were transected, leaving the sural branch intact. The muscle was sutured with 4-0 silk sutures and 
the wound was closed with 9-mm metal clips, followed by Neosporin®.
Behavioral testing. Behavioral testing was conducted at baseline and 3, 8, 11, 14, 17, 21, 28, 35, 42, and 54 
days post-SNI. In a separate cohort of rats, spinal cord tissue and dorsal root ganglia tissue were collected at 14 
days post-SNI surgery for immunohistochemistry. For naïve studies, rats received rotarod training for 2 days, 
then received intrathecal injection of NPY-saporin or blank-saporin. Testing in these rats was completed 2–3 
weeks post intrathecal injection.
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Mechanical Hyperalgesia, von Frey. To evaluate sensitivity to a non-noxious mechanical stimulus, we used an 
incremental series of 8 von Frey filaments of logarithmic stiffness (0.4–15 grams). The 50% withdrawal threshold 
was determined using the Up-Down method27. Each filament was applied perpendicular to the lateral hindpaw 
surface with sufficient force to cause a slight bending of the filament. A positive response was defined by a rapid 
withdrawal of the paw within 5 seconds.
Mechanical Hyperalgesia, noxious pin. To evaluate sensitivity to a noxious mechanical stimulus, we gently and 
rapidly applied the point of a dull pin to the lateral aspect of the hind paw, avoiding damage to the skin. The 
duration of time with which the animal raised this paw was recorded, with a cut-off of 30 seconds. Three meas-
urements were averaged.
Mechanical hyperalgesia, paw pressure. To assess sensitivity to increasing noxious mechanical pressure, animals 
were lightly restrained while extending the hind paw. The plantar surface was placed on the plinth between the 
calipers of the Randall-Selitto device (IITC) and increasing gram force was gradually applied on the surface of 
the paw until the animal exhibited a withdrawal or vocalization. Three measurements of gram force at time of 
response were averaged.
Cold Allodynia, acetone drop. To evaluate the response to a cool stimulus, we used a piece of PE-90 tubing, 
melted at the tip, to apply a drop (10–12 ul) of acetone to the lateral aspect of the ventral hindpaw. The duration 
of time with which the animal raised this paw was recorded, with a cut-off of 30 sec. Three measurements were 
averaged.
Heat Hyperalgesia, Hargreaves’s irradiant heat. To evaluate the response to a heat stimulus, rats were placed in a 
clear Plexiglas box on a glass floor. The thermal stimulus consisted of a radiant heat source positioned under the 
glass floor directly beneath the hind paw. Voltage intensity was adjusted such that paw withdrawal latency was 
10 ± 0.5 seconds. If the animal did not respond within 20 seconds, the heat was discontinued to prevent damage 
to the paw. Withdrawal responses to three stimulus pairs, delivered every five minutes, were averaged.
Heat hyperalgesia, hot plate. To evaluate the response to a heated floor stimulus, a single rat was placed on a 48, 
52, or 56 °C surface within an acrylic enclosure (Columbus Instruments). The animal was immediately removed 
from the enclosure when it jumped, licked, or lifted a hind paw. Response latencies to three trials were averaged.
Motor coordination, rotarod. To evaluate motor coordination, rotarod testing was performed at 7 and 14 days 
post-saporin injection. Rats were trained on two training days prior to intrathecal injection. The rotarod acceler-
ated 0.5 rpm every 5 sec, with a maximum speed of 40 rpm. Training involved repeated placement on the rotarod 
until one of the following was achieved: exposure to 20 sessions, or successful performance of at least 150 sec-
onds for three consecutive trials. For experimental testing, rats were placed on the rotarod at one and two weeks 
post-intrathecal injection. Performance time, recorded in seconds, was determined when the animal fell off of the 
rotating bar, thus breaking a light beam. Five consecutive trials were averaged for each animal.
Integrated Exploratory Activity. To evaluate innate exploratory behaviors of rats in a dark novel “open field”, 
a single rat was placed in a clear Plexiglas box on a Plexiglas floor. We evaluated activity using the automated 
Photobeam Activity System (PAS) with Flexfield Animal Activity System (San Diego Instruments, Inc, San 
Diego), coupled to a computer to eliminate human interaction and bias. Using 32 infrared photobeams, six main 
parameters were measured in six 5−min intervals: rearing events, active time and resting time, beam breaks, and 
distance traveled.
Immunohistochemistry. Animals were deeply anesthetized with pentobarbital (Fatal Plus, diluted to 
200 mg/kg i.p., Med-Vet International, Mettawa, IL) and perfused transcardially with 200 ml of room temperature 
(RT), 0.01 M phosphate buffered saline (PBS) with heparin (10,000 USP units/L) followed by 300 ml of ice-cold 
fixative (10% buffered formalin). The cord was removed and post-fixed for 4 hr in 10% buffered formalin (4 °C) 
and then cryoprotected (30% sucrose in 0.01 M PBS for 36–96 hr). L4-L6 transverse sections (35–40 μm) were 
cut on a freezing microtome and collected in 0.01 M PBS. The sections were washed three times in 0.01 M PBS 
and then pretreated with 3% normal goat or donkey serum serum and 0.3% Triton X-100 to block non-specific 
binding. Sections were then incubated in a primary antibody, rabbit anti-Fos (1:20,000, Calbiochem), rabbit 
anti-Y1R (1:5,000, courtesy of Janice Urban), rabbit Anti-CGRP for mouse/rat (1:20,000, Bachem) and rab-
bit anti-NK1R (1:10,000, Neuromics) overnight at RT on a slow rocker. For fluorescence co-labeling studies, 
we used a rabbit anti-Y1R antibody (Neuromics) derived from the same antigen as that developed by Janice 
Urban and colleagues, but at a more concentrated dilution (1:500). Spinal cord sections were then co-incubated 
with Y1R antibody together with either markers of excitatory interneurons (mouse anti-calbindin, 1:1,000, 
Sigma; goat anti-calretinin, 1:5,000, Swant; guinea pig anti-PKCγ, 1:10,000, courtesy of Allan Basbaum; mouse 
anti-somatostatin, 1:500, GeneTex) or a marker of inhibitory interneurons (goat anti-Pax-2, 1:1,000, R&D 
systems). The tissue was then washed three times in 0.01 M PBS, and incubated at RT in secondary antibody 
for either enzyme (1:200 dilution) or fluorescent (1:700 dilution) labeling. Secondary antibodies used for the 
co-localization studies were: Alexa 568-conjugated goat anti-rabbit; Alexa 568-conjugated donkey anti-rabbit; 
Alexa 488-conjugated goat anti-mouse; Alexa 488-conjugated goat anti-guinea pig; Alexa 488-conjugated don-
key anti-goat (all 1:1,000; Invitrogen). For fluorescent IB4 labeling, tissue was incubated in a primary IB4 anti-
body conjugated to FITC (1:500, Sigma) and cover-slipped with Prolong Gold with DAPI mounting medium 
(Molecular Probes).
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Confocal microscopy, image processing, and quantification of Y1R co-localization with 
INs. Representative confocal images of Y1R co-labeling with markers of excitatory or inhibitory interneurons 
were acquired with a Leica ABOS TCS SP5 inverted laser scanning confocal microscope, fitted with a 100x oil 
immersion objective (numerical aperture 1.46). The microscope is a Leica DMI 6000 with LAS AF 2.7.2.9586 
software. Laser excitation lines and emission windows for the different fluorophores were: Alexa Fluor 488 - 
excitation 488 nm (Ar laser), emission 505–555 nm; Alexa Fluor 568 - excitation 543 nm (diode laser), emission 
565–615 nm; DAPI - excitation 405 nm (HeNe laser), emission 435–485 nm. Line averaging was used to decrease 
signal to noise ratio. Adobe Illustrator CS6 (Adobe Systems Inc., Mountain View, CA) was used to assemble the 
multi-panel figures.
Quantification of staining in randomly-selected sections was performed with NIS Elements Advanced 
Research software. To distinguish immunohistochemical staining patterns of tibial and sural terminals, we 
selected ROIs spanning the medial-central and central-lateral regions, respectively, of lamina II of the tibial and 
sural across the mediolateral axis of the dorsal horn. Only DAPI-labeled cells were counted. Three animals per 
group and three slices per animal were quantified for Y1R and/or calbindin, calretinin, PKCγ, or Pax-2.
Fluorescence microscopy, image processing, and quantification of Fos immunohistochemistry. 
Digital photomicrographs were captured from lumbar segment L4-L5 with a Nikon TE2000-E microscope with 
Metamorph software (Version 6.1r4, Universal Imaging Corp.). Immunoreactivity was quantified with NIH cus-
tom ImageJ software. Integrated density was determined by thresholding the images using the default algorithm 
within ImageJ to reduce background and include positively stained cells in spinal cord dorsal horns from the 
L4-L5 lumbar region. Integrated density of the region of interest (ROI) is equal to the product of ROI area and 
mean gray value. The mean gray value represents the sum of the intensity values for all pixels above the threshold 
in the ROI divided by the number of pixels above threshold within the ROI. This method controls for differences 
in background between slices and subjects. For quantification of Fos, an observer blinded to treatment manually 
counted punctate immunoreactive profiles in lamina I-V. Six animals per group and 4–6 slices per animal were 
quantified for Y1R, CGRP, IB4, or NK1R.
Statistical analysis. Data were analyzed using Prism software (GraphPad, San Diego CA). All data are 
expressed as mean ± SEM. Statistical significance was set at P < 0.05. Behavioral data were analyzed by two-way 
ANOVA with treatment as the between-subjects factor and time as the within-subject factor. Other data were 
analyzed by one-way or two-way ANOVA and Bonferroni or Tukey’s post-hoc tests, or unpaired, two-tailed stu-
dent T-tests.
Results
Expression of Y1R with markers of excitatory but not inhibitory interneurons in dorsal 
horn. Y1R immunoreactivity (Y1R-ir) in the dorsal horn presents as a dense plexus of axons and dendrites 
that complicates analysis of co-labeling. We reduced this problem by pretreating animals with two intrathecal 
injections of NPY (30 µg) separated by 1 hour so as to promote receptor internalization, thereby concentrating 
Y1R from more distal dendritic locations to within the cell soma. As illustrated in Fig. 1, NPY pretreatment con-
centrated Y1R-ir within the cell soma, thereby permitting a more accurate assessment of spinal Y1R-expressing 
populations. We found Y1R-ir to co-localize with multiple markers of excitatory neurons in superficial lamina: 
calbindin (Figs 1A,B and 2A), calretinin (Figs 1C,D and 2B), and somatostatin (Fig. 1I), but neither PKCγ-ir 
(which labels a band in inner lamina II) (Figs 1E,F and 2D) nor Pax2-ir (a marker of inhibitory neurons) 
(Figs 1G,H and 2C).
The colocalization of Y1R and somatostatin is consistent with studies utilizing Y1R-ir18 and transcriptional 
profile analyses28. Neuronal phenotypes can be classified based upon the transcription factors that regulate the 
development of their lineage29–31. Notable is Pax2, which continues to be expressed in mature GABAergic neurons. 
We found very little co-localization with Pax2 (Fig. 2C), and therefore our results indicate that Y1R-expressing 
cells represent a large subpopulation of excitatory but not inhibitory interneurons.
NPY-saporin selectively ablated Y1R-expressing spinal interneurons. The highest dose of 
NPY-saporin in Wiley et al. (2009) was 750 ng. This dose reduced Y1R immunoreactivity in the dorsal horn by 
approximately 40% (see their Table 1)21. In an attempt to lesion a greater number of Y1R-expressing neurons, 
we used not only the 750 ng dose, but also a higher dose of 1000 ng. As illustrated in Fig. 3(A–C), we found 
that the 1000 ng dose reduced Y1R staining by approximately 50% as compared to control treatment with an 
injection of a scrambled peptide conjugated to the saporin toxin. To determine the selectivity of intrathecal 
NPY-saporin for Y1R spinal interneurons, we evaluated not only Y1R-ir, but also NK1R (a marker of spinal cord 
nociception-responsive projection neurons that ascend to the brain), as well as CGRP and IB4 (markers of the 
central terminals of primary afferent terminals). By contrast, NPY-saporin did not change NK1R-ir, IB4-ir or 
CGRP-ir relative to the blank-saporin (P > 0.05; Fig. 3D–L). These findings indicate that Y1R-expressing primary 
afferents and projection neurons were spared by the toxin, and are consistent with Wiley and colleagues who 
reported that intrathecal NPY-saporin did not change the number of Y1R-expressing DRG neurons, nor dorsal 
horn staining for either NK-1R or mu opiate receptor (MOR) as compared to blank-saporin21.
NPY-saporin reduced the development and maintenance of neuropathic pain without chang-
ing normal motor behaviors or nociception. Previous studies indicate that NPY-saporin decreased 
behavioral signs of early inflammatory pain24, including Phase II of the formalin test, and reduced hotplate reflex 
responses to low (44 °C) intensity heat21. To determine the contribution of Y1R-expressing dorsal horn neurons 
to chronic neuropathic pain, we delivered NPY-saporin 14 days prior to SNI and evaluated the progression of 
nerve-injury induced hyperalgesia and allodynia over several weeks. SNI produced mechanical hypersensitivity 
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(von Frey), cold hypersensitivity (acetone drop), and mechanical hyperalgesia (blunt pin prick) that peaked at 
approximately 21 days in blank-saporin-treated control rats (Fig. 4). While both mechanical and cold hypersen-
sitivities reached a steady-state that was maintained until at least 54 days post-SNI, pin prick mechanical hyperal-
gesia gradually decreased from Day 28 through Day 54. Relative to rats treated with blank-saporin, NPY-saporin 
Figure 1. Y1R-expressing profiles often co-express calbindin, calretinin, and/or somatostatin, but neither PKCγ 
nor Pax2. Co-staining of Y1R with DAPI and antibodies against (A,B) calbindin, (C,D) calretinin, (E,F) PKCγ, 
(G,H) Pax2, or (I) somatostatin. Confocal images of transverse L4-L6 sections were taken with a 100X objective 
from lamina II. Dorsal side is up. Images in B, D, F, and H are zoomed in from the white square boxes shown in 
A, C, E, and G, respectively. Arrows indicate instances of Y1R colabeling. Scale bars: 10 µm.
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dose-dependently reduced mechanical hypersensitivity (Treatment: F2,20 = 6.42, P = 0.007), cold hypersensi-
tivity (Treatment: F2,20 = 9.76, P = 0.0011), and mechanical hyperalgesia (Treatment: F2, 20 = 13.43, P = 0.0002). 
Secondary analysis of each NPY-saporin group compared to the blank-saporin control group revealed that the 
750 ng dose did not change behavioral signs of neuropathic pain at earlier (Days 3–17) timepoints (P > 0.05), but 
decreased vF mechanical hypersensitivity (F1,13 = 12.0, P = 0.0042), cold hypersensitivity (F1,13 = 4.53, P = 0.05), 
and mechanical hyperalgesia (F1, 13 = 5.29, P = 0.039) at later timepoints (Days 21–54). By contrast, the 1000 ng 
dose of NPY-saporin decreased behavioral signs of neuropathic pain at both earlier timepoints (Days 3–17): 
vF mechanical hypersensitivity (F1,15 = 7.93, P = 0.013), cold hypersensitivity (F1,15 = 8.20, P = 0.012), pin prick 
mechanical hyperalgesia (F1, 15 = 14.0, P = 0.002), as well as later timepoints (Days 21–54): vF mechanical hyper-
sensitivity (F1,15 = 14.2, P = 0.0019), cold hypersensitivity (F1,15 = 18.0, P = 0.0007) and mechanical hyperalgesia 
(F1,13 = 25.4, P = 0.0001).
Analysis of area under the curve (AUC) illustrates that effect size depends on the somatosensory modality, 
time of testing after injury, and dose of NPY-saporin, Thus, while the 750 ng dose did not change mechanical 
withdrawal thresholds as compared to blank-saporin controls over Days 3–17 (just a 1.6% increase), it produced 
a quite robust, greater than 3-fold increase in mechanical thresholds over Days 21–54 (360% increase); also the 
750 ng dose decreased behavioral signs of noxious mechanical hyperalgesia and cold allodynia by approximately 
one-third regardless of timepoint (Days 3–17: 30.3% reduction in cold withdrawal response, 32.3% increase in 
pin prick withdrawal; Days 21–54: 36.3% reduction in cold withdrawal response, 33.7% increase in pin prick 
withdrawal). The 1000 ng dose produced even greater effects as compared to blank-saporin controls over Days 
3–17 (increased mechanical withdrawal thresholds by 114%, reduced cold withdrawal response by 68.5%, and 
increased pin prick withdrawal by 74.4%) and Days 21–54 (increased mechanical withdrawal thresholds by 
458%, reduced cold withdrawal response by 64.6%, and increased pin prick withdrawal by 66.8%). In summary, 
the effects of NPY-saporin on neuropathic pain behaviors are strongest at later timepoints, and the higher dose 
recruits an additional effect on mechanical allodynia at early timepoints.
We evaluated the effect of NPY-saporin on numerous parameters of acute pain and motor control (Fig. 5). 
As compared to blank-saporin, NPY-saporin did not change thermal or mechanical sensitivity, body weight, 
motor coordination, ambulatory behavior, nor exploratory behaviors in an open field activity box (P > 0.05). 
This data suggests that the anti-hyperalgesia effects of NPY observed in Fig. 4 do not apply to all modalities of 
acute nociception, and are not confounded by motor side effects. Our results indicate that NPY-saporin did not 
change hindpaw withdrawal thresholds in response to application of noxious heat at 48 °C, 52 °C, or 56 °C. This 
is consistent with Wiley et al. (2009) who reported no effect in response to 47 °C or 52 °C (antinociceptive effects 
were observed only at a much lower temperature of 44 °C)21.
Figure 2. Quantification of Y1R co-localization. Quantification of colocalization in medial and central dorsal 
horn of (A) Calbindin-ir, (B) Calretenin-ir, (C) Pax2-ir, and (D) PKCγ-ir with Y1R-ir. The relative distribution 
of subpopulations of Y1R-expressing neurons as determined by % colocalizations can be seen in (E,F). N = 3 
rats per antibody with N = 3 transverse sections averaged per animal.
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Nerve injury does not decrease NPY-Y1R signaling in the dorsal horn. Peripheral nerve injury 
decreases the expression of several neuropeptide transmitters and receptors in dorsal root ganglion and spinal 
cord27,32, as well as the signal transduction of pain inhibitory GPCRs in in the brain33. For example, injury-induced 
decreases in the dorsal horn expression of the mu opioid receptor is accompanied by decreases in capacity for 
opioid-induced analgesia34,35, a mechanism that might explain the poor efficacy of opioid analgesics for neuro-
pathic pain36. Whether nerve injury produces similar changes in Y1 signaling and responsiveness to NPY antino-
ciception is unknown. To address this question, we evaluated Y1R density and NPY-induced FOS activation 
of Y1R-expressing neurons after SNI. We used a polyclonal antibody whose Y1R specificity in rat tissue was 
confirmed using western analysis, preadsorption of the antibody with peptide, and preimmune serum controls37.
As previously described15, we observed a pattern of intense Y1R-ir in lamina I-II comprised of tightly-packed 
cell bodies, embedded in Y1R-expressing processes, surrounded by CGRP-ir nerve endings (Fig. 6A), and over-
lapping with IB4-positive cells (Fig. 6B). As expected, SNI substantially reduced CGRP and IB4 immunoreactivity 
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Figure 3. NPY-saporin lesion selectively reduces Y1R-ir in the dorsal horn. Y1R, CGRP, NK1, or IB4 
immunostaining in the dorsal horn of naïve rats 14 days after intrathecal injection of (A,D,G,J) blank saporin 
or (B,E,H,K) 1000 ng NPY-saporin. NPY-saporin decreased (C) Y1R but did not change immunostaining 
in the dorsal horn of (F) CGRP, (I) NK1-R or (L) IB4 as compared to blank-saporin controls. Values are 
expressed as integrated density of staining in dorsal horn. ★P < 0.05 compared to blank-saporin. Data represent 
mean ± SEM. Scale bars: 100 µm.
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within the innervation territories of the tibial and common peroneal nerves (Fig. 6C,D). By contrast, SNI only 
slightly reduced spinal Y1R-ir density within just the tibial and not the common peroneal innervation territory 
(Fig. 6E,F). While this slight immunoreactive reduction likely represents loss of Y1R expressed on the central 
terminals of primary afferent neurons that terminate in the IB4 positive laminar band, the small effect here is 
consistent with preliminary reports suggesting that “light” or “medium” chronic constriction injuries impact 80% 
or less of the sciatic nerve and, thus, would not substantially reduce spinal Y1R-ir density16.
We next evaluated the effect of NPY on neuronal activity in Y1R spinal interneurons during neuropathic 
conditions. After intrathecal administration of NPY, we quantified the co-expression of Fos and Y1R in dorsal 
horn neurons. We found that intrathecal NPY increased von Frey thresholds (Fig. 7A, P < 0.05) and reduced the 
number of Fos-expressing cells in the dorsal horn (Fig. 7B, P < 0.01). Importantly, NPY decreased Fos expression 
within Y1R-expressing neurons (Fig. 7C, P < 0.05). In summary, peripheral nerve injury spares spinal Y1R den-
sity and responsiveness of Y1R neurons to NPY. These studies indicate that the Y1R retains the capacity to inhibit 
spinal pain transmission after nerve injury.
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Figure 4. Lesion of Y1R-expressing spinal neurons reduces the severity of neuropathic pain. (A,C,E) 
Intrathecal NPY-saporin (750 ng or 1,000 ng) reduced the development of (A) mechanical hypersensitivity 
to von Frey filaments (F2,20 = 5.516, P = 0.01), (C) cold response duration during acetone evaporation 
(F2,20 = 9.889, P = 0.001), and (E) mechanical response duration to blunt pin (F2,20 = 13.43, P = 0.0002), 
compared to intrathecal Blank-saporin. Repeated Measures Two-way ANOVA + Bonferonni. (B,D,F) Area 
Under the Curve (AUC) analyses for days 3–17 (P < 0.05 for all panels) and 21–54, respectively. One-way 
ANOVA + Bonferonni. N = 6–9 per group. ★P < 0.05 compared to Blank-saporin. Dots represent individual 
subjects within the analysis. Data represent mean ± SEM.
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Discussion
The key finding of the present studies is that selective ablation of Y1R-expressing neurons in the dorsal horn 
delayed the onset and reduced the intensity of behavioral signs of neuropathic hyperalgesia after peripheral 
nerve injury. The effect was broad spectrum, impinging upon multiple somatosensory modalities including 
non-noxious mechanical, noxious mechanical, and cold hypersensitivity. These results further support spinal 
Y1R as a potential target for the pharmacological treatment of chronic pain.
Y1R-expressing spinal excitatory interneurons contribute to neuropathic pain. Calbindin 
and calretinin are primarily located in different sub-populations of dorsal horn neurons and are largely (but 
not exclusively) restricted to glutamatergic cells38–40. For the first time, we show that both are contained in 
Y1R-immunoreactive neurons. PKCγ-ir neurons are present throughout laminae I–III41,42, particularly in the 
inner half of lamina II, where their dendrites form a dense plexus43,44. Although PKCγ-ir cell bodies make 
numerous contacts with NPY-positive boutons and dendrites45 and thus might appear to be a candidate for 
co-expression with Y1R, this population is largely distinct from the calbindin and calretinin populations and 
did not colocalize with Y1R in the current study. We conclude that the vast majority of Y1R-expressing cells are 
excitatory interneurons that lie dorsal to the inner lamina II band that is demarcated by PKCγ staining.
We found that Y1R-ir neurons in lamina II typically contain somatostatin18. Most somatostatin-containing 
boutons contain the vesicular glutamate transporter 2, VGLUT219, and somatostatin lineage-TdTomato cells 
extensively co-label with Vglut2 mRNA5. Because excitatory interneurons and their boutons in the dorsal horn 
express VGLUT219,46,47, it is highly likely that somatostatin-expressing neurons are excitatory. Furthermore, selec-
tive ablation of somatostatin lineage neurons, using an intersectional genetic strategy, decreased mechanical allo-
dynia associated with SNI in the mouse, suggesting that spinal somatostatin-expressing excitatory interneurons 
transmit neuropathic mechanical information5. This is consistent with the present results showing that deletion of 
Y1R neurons, and thus a subset of somatostatin neurons, decreased the neuropathic allodynia in the rat.
In addition to novel immunohistochemical profiling of neuropeptide and neurotransmitter neuron popula-
tions of the dorsal horn, significant progress has been made in the past decade in understanding the development 
of dorsal horn spinal neuron lineages. Of note is the uncovering of specific transcription factors that determine 
the excitatory (glutamatergic) or inhibitory (GABAergic/glycinergic) cell fate of spinal dorsal horn neurons48–50. 
In support of our studies, Npy1r gene expression is almost exclusively found in Tlx3+ glutamatergic neurons, 
and rarely found in Pax2+ GABAergic neurons51. Further, transcriptomic profiling analysis has determined that 
Npy1r mRNA is significantly enriched in the somatostatin dorsal horn neuron population28. Single-nucleus 
RNA sequencing has clustered Npy1r into a dorsal excitatory peptidergic neuron cluster52, and single-cell RNA 
sequencing has classified Npy1r neurons as excitatory glutamatergic interneurons53.
Y1R interneurons contribute to the development and maintenance of neuropathic pain. The 
effect of NPY-saporin on the development (early timepoints) and maintenance (late timepoints) of allodynia and 
hyperalgesia varied with dose and somatosensory modality. For example, the 750 ng dose did not change von 
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Figure 5. Lesion of Y1R-expressing spinal neurons does not alter basal nociception or motor control. The effect 
of intrathecal blank-saporin or NPY-saporin (1000 ng) on rat nociceptive behavior in the (A) hotplate assay 
and (B) Hargreave’s thermal assay for heat hyperalgesia, and the (C) Randel-Siletto paw pressure assay and the 
(D) von Frey filament assay for mechanical sensitivity. (E) Neither blank-saporin nor NPY-saporin changed 
body weight. The effect of intrathecal blank-saporin or NPY-saporin (1000 ng) on rat motor behavior in the (F) 
Rotarod test for motor coordination, and (G–K) general activity measures in an open field arena. Dots represent 
individual subjects within the analysis. Data represent mean ± SEM.
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Figure 6. Peripheral nerve injury largely spares Y1R expression in the dorsal horn. (A,B) In uninjured rats, 
Y1R immunostaining of lumbar spinal cord slices shows minimal colocalization with the afferent terminal 
markers (A) CGRP and (B) IB4. SNI largely spared Y1R in contrast to large decreases in (C) CGRP and (D) IB4. 
(E) Quantification of Y1R immunostaining across the entire mediolateral axis of the dorsal horn revealed no 
significant overall loss of Y1R. (F) Segregation of the dorsal horn by the innervation zones of the tibial (medial, 
M), common peroneal (central, C) or sural (lateral, L) branches of the sciatic nerve revealed a slight decrease in 
Y1R density in the tibial innervation zone relative to controls. Control, N = 4; SNI, N = 8. ★P < 0.05 compared 
to control. Data represent mean ± SEM. Dots represent individual subjects in the analysis.
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Frey mechanical threshold at earlier timepoints, but exerted a robust increase in threshold at later timepoints. 
By contrast, the 1000 ng dose of NPY-saporin reduced mechanical thresholds (and cold and pinprick responses) 
at all timepoints. The additional efficacy of the higher NPY-saporin dose at earlier timepoints suggest that two 
subpopulations of Y1R-expressing interneurons differentially control the early development and the long-term 
maintenance of nerve injury-induced mechanical allodynia. Thus, in addition to a Y1R-expressing subpopulation 
that maintains neuropathic pain and is vulnerable to 750 ng NPY-saporin, there is an additional subpopulation 
that drives the development of neuropathic pain and is only vulnerable to the 1000 ng dose.
These studies are the first to implicate Y1Rs and Y1R-expressing dorsal horn neurons in the development of 
neuropathic pain and are consistent with previous studies indicating that Y1Rs contribute to the maintenance 
of neuropathic pain. For example, intrathecal administration of neuropeptide Y or the selective Y1R agonist 
Leu31 Pro34 dose-dependently reversed established markers of neuropathic pain including hyperalgesia and 
stimulus-evoked Fos expression in the dorsal horn9,11. Further studies are needed to determine whether ablation 
or inhibition of Y1R-expressing neurons, with either intrathecal administration of NPY-saporin or optogenetic 
or chemogenetic inhibition of Y1R-expressing neurons utilizing cre driver lines, will inhibit established signs of 
neuropathic pain when administered days to weeks after peripheral nerve injury.
NPY-saporin selectively targets Y1R interneurons rather than central terminals of primary 
afferent neurons or spinal projection neurons. Y1Rs are expressed on small- to medium-sized DRG 
neurons and spinal cord neurons14,54,55. Since intrathecal NPY-saporin could conceivably cross the fibrous 
sheath that encases the DRG (as observed with GFP-conjugated viral particles), or be taken up by terminals of 
Y1R-expressing primary afferents, and attack peripheral Y1R-containing cells, one might predict that intrathecal 
NPY-saporin would kill not only Y1R-containing dorsal horn neurons but also DRG neurons and their unmy-
elinated afferents that terminate in lamina I/outer part of lamina II (CGRP-containing) or in the inner part of 
lamina II (isolectin B4-containing). This is unlikely for several reasons. First, the current studies indicate that 
NPY-saporin did not change CGRP and IB4 staining in the dorsal horn. Second, spinal Y1R does not readily 
co-stain with CGRP, SP, or IB414,55 and is unchanged following dorsal rhizotomy54, indicating that its existence on 
the central terminals of primary afferents is sparse at best. Third, Wiley and colleagues reported that intrathecal 
NPY-saporin had no effect on Y1R cell counts in DRG of the fourth lumbar spinal segment21, indicating insuffi-
cient penetration into the DRG. Lastly, the vast majority of NPY Y2 receptors in the dorsal horn are found on the 
central terminals of primary afferents56, but a recent single-cell RNA sequencing analysis suggests the existence 
of Y2 receptors on a few interneurons53. We cannot exclude that these very few Y2R-expressing neurons were 
affected by NPY-saporin but consider it highly unlikely that this would affect the conclusions drawn in our study, 
as has been previously concluded21. Therefore, we conclude that the vast majority of Y1R immunoreactivity is 
located on dorsal horn neurons, and that NPY-saporin selectively ablates this Y1R-containing population of neu-
rons, rather than Y1R- or Y2R-positive terminals of primary afferent neurons.
Similar lack of effect on DRG neurons has been reported after intrathecal injection of dermorphin-saporin, 
a mu opiate receptor-specific toxin57. In that study, dermorphin-saporin injections destroyed lamina II 
MOR-expressing interneurons but had no effect on MOR-expressing DRG neurons. Although immunotoxins, 
such as OX7-saporin, 192-saporin and anti-dopamine beta-hydroxylase saporin are effective suicide transport 
agents (killing target neurons after selective uptake into axon terminals, followed by retrograde axonal trans-
port to cell bodies where saporin acts to induce cell death), there is considerable evidence that intrathecal 
neuropeptide-saporin conjugates do not affect DRG neurons21,57,58. Thus, there is a key difference between immu-
notoxins which are effective suicide transport agents and neuropeptide-toxin conjugates which are not.
Y1R-ir cells exhibited retrograde labeling in lamina I, V, and X after choleratoxin B injection at the level of the 
9th thoracic segment, and therefore project, at least, to the lower thoracic levels15 and likely on to the brainstem 
and diencephalic areas for further processing of nociceptive signals4. The majority of lamina I projection neurons 
and some in the deeper laminae express the NK1 receptor59,60, particularly those with a multipolar or fusiform 
shape61, and it is the latter which are Y1R-expressing15. However, consistent with previous studies21, we found that 
NPY-saporin did not change NK1R-immunoreactivity in the superficial dorsal horn, indicating that the mech-
anism by which NPY-saporin decreases neuropathic pain does not directly implicate NK1 receptor-expressing 
Figure 7. NPY reduces neuropathic mechanical hypersensitivity and light touch-evoked c-Fos expression in 
Y1R+ dorsal horn neurons. (A) von Frey thresholds 14 days after SNI before (pre-injection) and 60 min after 
intrathecal injection of saline or NPY (post-injection). Non-noxious mechanical stimulus-evoked expression 
of Fos-immunoreactivity in lamina I-II (B) for all neurons and (C) in Y1R-immunoreactive neurons. N = 6–9. 
★P < 0.05 compared to control. Data represent mean ± SEM. Dots represent individual subjects in the analysis.
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projection neurons. Furthermore, we do not believe that NPY-saporin targeted NK1 receptor-negative, large 
pyramidal-shaped projection neurons in lamina I62, because those do not express the Y1R receptor15. Although 
we cannot exclude a contribution of NK1 receptor-negative neurons in deeper laminae, their numbers are small 
and so we conclude that the mechanism by which NPY-saporin reduces neuropathic pain is most likely due to 
ablation of Y1R-expressing interneurons, rather than projection neurons, in the dorsal horn.
The Y1R retains its functional responsiveness to the pain inhibitory actions of NPY in the set-
ting of nerve injury. Peripheral nerve injury decreases the expression of opioid receptors34,35 and the ability 
of agonists to inhibit synaptic transmission in the dorsal horn35. Such mechanisms might explain the poor efficacy 
of opioid analgesics for neuropathic pain36. By contrast, we report that nerve injury did not decrease spinal Y1R 
expression. Instead, intrathecal administration of NPY reduced nerve injury-induced mechanical hyperalgesia 
as well as stimulus-evoked gene expression (using Fos as a marker) on the Y1R-expressing population of dorsal 
horn neurons, consistent with and extending our previous studies9. This supports our suggestion that the Y1R, 
in contrast to the mu opioid receptor, has greater capacity for endogenous pain relief12, and thus may be superior 
to opioids as a pharmacological target for long-lasting relief from neuropathic pain, particularly when adminis-
tered at the spinal level22. In summary, our neuroanatomical and behavioral characterization of Y1R-expressing 
excitatory interneurons provides compelling evidence for the development of spinally-directed Y1R agonists to 
reduce chronic neuropathic pain.
Does endogenous NPY act at Y1R-expressing neurons to tonically inhibit neuropathic pain? 
When administered at the spinal level, NPY Y1 receptor agonists exert a broad-spectrum inhibition of pain22. 
This action is particularly robust in peripheral nerve injury models of neuropathic pain11, as intrathecal NPY 
has little effect on thermal thresholds in uninjured animals, but dose-dependently reduces behavioral signs of 
tactile and thermal hyperalgesia after injury, effects that can be blocked with a Y1R-selective antagonist9. These 
pharmacological actions mimic the tonic inhibitory control of neuropathic pain by endogenous NPY12. Indeed, 
our results are consistent with the hypothesis that NPY-Y1R signaling counters facilitatory mechanisms of neu-
ropathic pain following peripheral nerve damage.
The classic Gate Control Theory (GCT) of pain postulated that the input generated by nociceptive as well 
as non-nociceptive afferents is regulated by a complex, gated circuit in the dorsal horn. One of the central ten-
ets of GCT is that an inhibitory interneuron in the substantia gelatinosa responds to non-nociceptive input by 
inhibiting, or closing the gate on, a neuron that transmits pain messages to the brain63. Recent studies indicate 
that gating might also occur at excitatory interneurons, including those that express somatostatin, VGLUT3, 
or PKCγ5,7,64. Based on a large body of anatomical, behavioral, transcriptomic, and electrophysiological evi-
dence, we speculate that the Y1R-expressing excitatory interneurons described here would be gated by inhibitory 
NPY-expressing interneurons that release NPY22. First, extensive anatomical evidence describes a large subset of 
GABA-expressing dorsal horn interneurons that co-express NPY45. Second, we reported that endogenous NPY 
tonically inhibits neuropathic pain behavior12. Third, Smith and colleagues described inhibitory actions of NPY 
on the neurophysiological activity of dorsal horn neurons65.
These results shed further light on the mechanism by which endogenous NPY tonically inhibits peripheral 
neuropathic pain, and we conclude this likely occurs via the hyperpolarization of Y1R-expressing excitatory 
interneurons, rather than through disinhibition of Y1R expressing inhibitory interneurons as we have earlier 
postulated22. Our results highlight the importance of endogenous NPY-Y1R signaling in chronic pain regulation 
and provide a foundational mechanism for the targeting of spinal Y1R-expressing excitatory interneurons as a 
promising target for pharmacotherapies to treat clinical neuropathic pain.
Data Availability
The datasets generated during and/or analyzed during the current study will be made available from the corre-
sponding author on request.
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